DCVAC/OvCa After Standard-of-care Chemotherapy in Women With Relapse of Platinum-sensitive Epithelial Ovarian Cancer

Inclusion Criteria: * Patients with histologically confirmed FIGO stage III or IV epithelial ovarian, primary peritoneal or fallopian tube carcinoma (serous,endometrioid, or mucinous) who had complete remission after first-line platinum-based chemotherapy * Radiologically confirmed relapse after \>6 months of remission ( platinum-sensitive cancer) * Laboratory parameters per protocol Exclusion Criteria: * FIGO I, II epithelial ovarian cancer * FIGO III, IV clear cells epithelial ovarian cancer * Non-epithelial ovarian cancer * Borderline tumors ( tumors of low malignant potential) * Prior or current systemic anti-cancer therapy for ovarian cancer (chemotherapy, monoclonal antibody therapy, tyrosine kinase inhibitory therapy, vascular endothelial growth factor or hormonal therapy) except first-line Pt based chemotherapy ( with or without bevacizumab) * fertile women of child-bearing potential not willing to use a highly effective method of contraception or a combination of methods * Pregnant of lactating women * Pre-defined co-morbidities * Known hypersensitivity to any constituent of DCVAC/OVCa or the selected chemotherapy compounds